We next examined the effects of CPI203 and BTZ in a primary patient bone marrow sample from a patient with relapsed-refractory MM with 90% marrow involvement, who had previously taken BTZ and progressed on carfilzomib (2nd generation proteasome inhibitor). The gene discussed is CASC3; the disease is Miyoshi myopathy.